Back to mobile site

BMO Capital Downgrades Amylin Pharmaceuticals (AMLN) to Underperform

March 4, 2010 7:31 AM EST Send to a Friend
BMO Capital downgrades Amylin Pharmaceuticals (Nasdaq: AMLN) from Market Perform to Underperform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login